COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s): CSCI

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

TSX:CSCI - Post by User

COSCIENS Biopharma Inc > October 8 Abstract Presentation:

<< Previous

Bullboard Posts

Next >>

Comment by Hopeforthebeston Oct 05, 2024 8:27pm

37 Views

Post# 36254808

RE:October 8 Abstract Presentation:

Well with the patent to expire shortly a lot of good the delayed off start up means little
another example of gagnon's failure to live up to promises and deliver in a timely manner

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages